Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zuzanna Krupa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge

    by Joanna Wrona, Zuzanna Krupa, Marta Zawadzka, Julia Rydzek, Adrian Muzyka, Karolina Dorobisz, Katarzyna Pazdro-Zastawny

    Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease with a complex pathogenesis that significantly affects patients’ quality of life. Type 2 inflammation plays a dominant role in its course and is associated with the activation of immune pathways involving interleukins IL-4, IL-5 and IL-13, eosinophils, and immunoglobulin E. Standard treatment methods, including corticosteroids and surgical interventions, despite their proven efficacy, often fail to provide sustained disease control and are associated with a high rate of recurrence. The aim of this review is not only to summarize the available evidence on biological therapies in CRSwNP, but also to critically evaluate their current position within treatment algorithms, with particular emphasis on patient selection, integration with endoscopic sinus surgery, comparison of available biologic mechanisms, and remaining challenges in personalized treatment strategies. The paper discusses available monoclonal antibodies, such as dupilumab, omalizumab, mepolizumab, and benralizumab, which act by selectively inhibiting key mediators of type 2 inflammation. Analysis of clinical trial results indicates that biological therapies lead to a significant reduction in nasal polyp size, improvement in nasal patency, restoration of olfactory function, and enhancement of quality of life as measured by the SNOT-22 scale. Furthermore, they demonstrate a favourable safety profile and may represent an effective therapeutic option for patients with severe, treatment-resistant disease, particularly in cases with coexisting eosinophilic asthma. Biological therapies represent a breakthrough in the treatment of CRSwNP and align with the concept of personalised medicine. Their role in clinical practice continues to expand; however, further research is required to optimise patient selection and assess long-term treatment outcomes.

  • Open Access

    Cellular Senescence in Neurodegeneration: From Cell Types to Therapeutic Opportunities

    by Marta Zawadzka, Julia Rydzek, Julia Lizon, Zuzanna Krupa, Joanna Wrona, Sławomir Woźniak

    Neurodegenerative diseases of the central nervous system, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, represent a growing health challenge in ageing populations. Among the mechanisms underlying these disorders, increasing attention has been directed toward the role of cellular senescence. This process, triggered by chronic cellular and oxidative stress as well as DNA damage, leads to irreversible cell-cycle arrest and the development of the senescence-associated secretory phenotype (SASP). Within the central nervous system, the accumulation of senescent cells induces chronic inflammation, blood–brain barrier disruption, and progression of neurodegenerative processes. In this review, we present current evidence regarding the mechanisms of cellular senescence in the central nervous system, with particular emphasis on the role of SASP in neuroinflammation, vascular dysfunction, and neural tissue damage. Experimental and clinical data supporting the involvement of cellular senescence in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis are discussed. The review also covers methods for identifying senescent cells in the brain, including molecular marker-based approaches and machine learning-based tools. Importantly, we discuss the methodological limitations of commonly used senescence markers, such as their limited specificity and the risk of false-positive detection, particularly in the heterogeneous cellular environment of the central nervous system. Strategies to improve detection reliability discussed in this review include the use of multimarker signatures, analysis of SASP components using qRT-PCR and ELISA, as well as transcriptomic approaches such as RNA sequencing and single-cell RNA sequencing. Furthermore, we analyze therapeutic strategies targeting senescent cells—senolytics, senomorphics, and SASP modulation—together with their limitations and associated clinical challenges. The collected evidence indicates that precise characterization of senescent cell populations in the brain is essential for the development of disease-modifying therapies for neurodegenerative disorders.


  • Top Cited Papers
    Open Access

    The Role of Cellular Senescence and SASP in the Pathogenesis of Atherosclerosis and the Therapeutic Potential of Senolytic Strategies in Cardiovascular Diseases

    by Zuzanna Krupa, Joanna Wrona, Marta Zawadzka, Julia Rydzek, Julia Lizon, Paulina Kalemba, Konrad Kochman, Paweł Iwaszkiewicz, Robert Iwanowski, Sławomir Woźniak

    Cellular senescence is a permanent cell cycle arrest that plays a critical role in the development and pathogenesis of age-related diseases. This paper aims to present the biological mechanisms of cellular senescence and the role of the senescence-associated secretory phenotype (SASP) in the pathogenesis of atherosclerosis, as well as to discuss therapeutic strategies targeting senescent cells in cardiovascular diseases. Different types of cellular senescence are described, including replicative, stress-induced, and oncogene-induced senescence, along with the composition and regulation of SASP and its impact on chronic inflammation, endothelial dysfunction, vascular remodeling, and plaque destabilization. The involvement of senescent endothelial cells, vascular smooth muscle cells, and macrophages in the initiation and progression of atherosclerosis is also discussed. The paper reviews current research on senolytic and senomorphic therapies and highlights emerging approaches such as immunosenolytic and epigenetic interventions. The therapeutic potential of these strategies in reducing chronic vascular inflammation and improving plaque stability, as well as their limitations and challenges in clinical application, is emphasized.


  • Open Access

    Primary Ciliary Dyskinesia—Current Diagnostic and Therapeutic Approach

    by Joanna Wrona, Zuzanna Krupa, Marta Zawadzka, Julia Rydzek, Karolina Dorobisz, Julia Bania

    Primary ciliary dyskinesia (PCD) is a rare, inherited disease with a complex genetic etiology, leading to ciliary dysfunction and impaired mucociliary clearance. This paper presents the current state of knowledge regarding the clinical presentation, diagnostic approaches, and therapeutic strategies in PCD. The role of genetic testing, ultrastructural analysis of cilia, and modern methods such as high-speed video microscopy (HSVA), nasal nitric oxide (nNO) measurement, and immunofluorescence is discussed. The importance of a multi-step diagnostic process is emphasized, given the absence of a single test with both high sensitivity and specificity. Current treatment options—including respiratory physiotherapy, infection management, and control of ENT symptoms—are reviewed, alongside new experimental approaches such as gene and mRNA therapies. This paper highlights the need for early diagnosis and comprehensive, interdisciplinary care for patients with PCD.